Adial pharmaceuticals inc ADIL.US 總覽分析
ADIL 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分較低，若以價值投資為目標，已經有長期投資部位可能需陸續減碼
ADIL 近期報酬表現
-0.33%
Adial pharmaceuticals inc
2.16%
同產業平均
0.70%
S&P500
與 ADIL 同產業的標的表現
- VANI Vivani medical inc價值 2 分趨勢 3 分波段 2 分籌碼 1 分股利 1 分查看更多
ADIL 公司資訊
Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of therapies for the treatment and prevention of addiction and related disorders. The Company's lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Company's ONWARD pivotal Phase III clinical trial for the potential treatment of AUD in subjects with certain target genotypes identified using the Company's proprietary companion diagnostic genetic test. AD04 is also used for the treatment of other addictive disorders, such as Opioid Use Disorder, obesity, smoking, and other drug addictions. The Company's wholly owned subsidiary is Purnovate, Inc.